Mass, MarceloArévalo, DiegoAleuanlli, IsidoraSantis, FernandaMaluenda, AndreaDines, EitanCohen, MiriamSaavedra, ÁlvaroRaby, TrinidadBlumel, BernarditaCuevas, RodrigoPohlhammer, SimoneAlarcon, GabrielaArellano, MarcoPizarro, Javier2024-12-162024-12-162024Mass-Lindenbaum M, Arévalo-Vega D, Aleuanlli I, Santis-Moya F, Maluenda A, Dines E, Cohen-Vaizer M, Saavedra Á, Raby T, Blumel B, Cuevas R, Pohlhammer S, Alarcon G, Albornoz MA, Pizarro-Berdichevsky J. Sacral neuromodulation therapy for urinary and defecatory disorders: experience in a Latin American public hospital. Rev Bras Ginecol Obstet. 2024 Mar 15;46:e-rbgo11. doi: 10.61622/rbgo/2024AO11https://hdl.handle.net/11447/9492Objective: To show the experience of a Latin American public hospital, with SNM in the management of either OAB, NOUR or FI, reporting feasibility, short to medium-term success rates, and complications. Methods: A retrospective cohort was conducted using data collected prospectively from patients with urogynecological conditions and referred from colorectal surgery and urology services between 2015 and 2022. Results: Advanced or basic trial phases were performed on 35 patients, 33 (94%) of which were successful and opted to move on Implantable Pulse Generator (GG) implantation. The average follow-up time after definitive implantation was 82 months (SD 59). Of the 33 patients undergoing, 27 (81%)reported an improvement of 50% or more in their symptoms at last follow-up. Moreover, 30 patients (90%) with a definitive implant reported subjective improvement, with an average PGI-I "much better" and 9 of them reporting to be "excellent" on PGI-I. Conclusion: SNM is a feasible and effective treatment for pelvic floor dysfunction. Its implementation requires highly trained groups and innovative leadership. At a nation-wide level, greater diffusion of this therapy among professionals is needed to achieve timely referral of patients who require it.enElectric stimulation therapyFecal incontinenceIncontinenceNon-obstructive urinary retentionSacral neuromodulationUrinary bladderoveractiveArticlehttps://doi.org/10.61622/rbgo/2024AO11